BHVN Biohaven Ltd.
Biohaven Ltd. (BHVN) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.6% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Biohaven Ltd.
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.
Sector
Healthcare
Industry
Biotechnology